Medicover Genetics has announced an upgraded liquid biopsy test, NeoThetis, which can detect cancer and its mutations through a simple blood draw, as per their press release.

The new Pan-Cancer Plus examination now offers a more comprehensive analysis, extending beyond the 200 genes and immunotherapy markers MSI and bTMB. This contributes to the advancement of more precise targeted therapy strategies for primary and metastatic cancers. Being non-invasive, the test reduces the challenges frequently associated with invasive tumor biopsy procedures.

Professor Filippos Patsalis, CEO of Medicover Genetics Cyprus, emphasized the clinical usefulness of the examination. He stated, "The enhanced NeoThetis Pan-Cancer Plus is a significant step towards improving personalized cancer care. Our aim is to bridge genetic knowledge with transformative patient care. Today, we are one step closer to achieving that goal."

Furthermore, the upgrade of the NeoThetis liquid biopsy provides healthcare professionals with the knowledge necessary for evidence-based decisions, thereby strengthening clinical management and personalized patient care.